Conveners
Parallel Session 8: Radiotherapy
- Daniel Hausermann (Australian Synchrotron)
The aim of our research is to undertake the first large animal trial of Microbeam Radiation Therapy (MRT) at the Australian Synchrotron to treat spontaneous cancers. The Imaging and Medical Beamline (IMBL) at the Australian Synchrotron is one of only four facilities in the world expressly designed to enable the clinical application of synchrotron radiotherapy for cancer patients. There are new...
Synchrotron microbeam radiation therapy (MRT) is a novel external beam therapy under investigation for its application in the treatment of brain tumours. Key characteristics of these x-ray microbeams is their high flux, high spatial fractionation and large dose rates. For clinical quality assurance, the dose rate in the microbeams (peaks) and between them (valleys) must be measured accurately....
Background: Synchrotron Microbeam Radiation Therapy (MRT) is a pre-clinical modality characterised by a periodically alternating peak-valley dose-distribution. Dosimetry studies using clinical datasets have not yet been conducted. Our aim was to identify optimal settings for a future Phase I trial from a range of clinical scenarios refractory to standard treatments.
Materials and methods:...
